We are Olema
Oncology.

Committed, tireless, and persistent.

We are committed to the discovery, development, and commercialization of a transformational generation of targeted therapies for women’s cancers.

Our team spent more than a decade conducting research, and has a deep insight into, endocrine-driven cancers. OP-1250 was the result of that persistence–the first compound designed to realize the Olema vision.

Our Team leadership board of directors

leadership

board of directors

leadership

Sean P. Bohen, M.D., Ph.D. President and CEO

Cyrus Harmon, Ph.D. Chief Technology Officer

Pamela M. Klein, M.D. Chief Medical Officer

Peter Kushner, Ph.D. Chief Scientific Officer

Shane Kovacs Chief Operating and Financial Officer

David C. Myles, Ph.D. Chief Development Officer

Kinney Horn Chief Business Officer

John B. Moriarty Jr., J.D. Executive Vice President and Chief Legal Officer

Leslie Hodges Gallagher, Ph.D. Senior Vice President, Discovery Biology

Sean P. Bohen, M.D., Ph.D. President and CEO

Ian Clark Chairman of the Board

Cindy Butitta Member

Sandra J. Horning, M.D., FACP, FASCO Member

Yi Larson, MBA Member

Andy Rappaport Member

Gorjan Hrustanovic, Ph.D. Member

Graham Walmsley, M.D., Ph.D. Member

Cyrus Harmon, Ph.D. Chief Technology Officer

Julie Dexter Vice President and Head of People

Demiana Faltaos, PharmD, Ph.D Vice President, Head of Clinical Pharmacology

David Kulp, PhD Vice President, Research Informatics

Kristin Lanzi Vice President, Information Technology

Florence Zhu, CPA Vice President, Finance & Controller

Ellen Ashley Vice President of Clinical Operations, Olema Oncology

Eva Stroynowski Vice President, Communications and Investor Relations

Meghna Chowdary Vice President of Competitive and Strategic Assessments

Our Science

We have a clear-eyed recognition of the limitations of current therapies and strategies, but have no intention of limiting what comes next.

Learn More

Our Pipeline

Olema has completed discovery and preclinical studies of OP-1250 required to file an IND and has begun clinical phase research. We anticipate exploring the potential applicability of OP-1250 in a range of metastatic breast cancers, as well as estrogen-driven gynecologic cancers.

Learn More

Press Releases

Here are the latest press releases from Olema.

For further information, visit Investors & Media.

Here are the latest press releases from Olema.

For further information, visit Investors & Media.

May 18th, 2021 Olema Oncology to Participate at the Jefferies 2021 Virtual Healthcare Conference SAN FRANCISCO, May 18, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P.
May 11th, 2021 Olema Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Update OP-1250 continues to advance in dose-escalation stage of Phase 1/2 clinical trial in patients with metastatic, ER+ / HER2- breast cancer; Initial data anticipated in 2H 2021 Cash, cash equivalents, and marketable securities of $327.0 million as of March 31, 2021 sufficient to fund operations
April 7th, 2021 Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced Sean P.
April 6th, 2021 Olema Oncology Appoints Oncology Biotech Executive Yi Larson, MBA, to Board of Directors Ms. Larson Brings Significant Biotech Operational Leadership and Global Healthcare Banking Expertise to Olema as the Company Continues to Advance Its Pipeline Longstanding Olema Director Dr. Frank McCormick to Transition from Board of Directors and Return to His Position as Chairman of Olema’s
March 17th, 2021 Olema Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates Advancing OP-1250 in metastatic, ER+ / HER2- breast cancer Phase 1/2 clinical trial Clinical trial agreements announced with Novartis and Pfizer to explore combination of OP-1250 with CDK4/6 inhibitors and PI3Kα inhibitor Approximately $382 million in gross proceeds raised across Series B, Series C
March 10th, 2021 Olema Oncology Announces Late-Breaking Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021 SAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation on
May 18th, 2021 Olema Oncology to Participate at the Jefferies 2021 Virtual Healthcare Conference SAN FRANCISCO, May 18, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P.
May 11th, 2021 Olema Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Update OP-1250 continues to advance in dose-escalation stage of Phase 1/2 clinical trial in patients with metastatic, ER+ / HER2- breast cancer; Initial data anticipated in 2H 2021 Cash, cash equivalents, and marketable securities of $327.0 million as of March 31, 2021 sufficient to fund operations
April 7th, 2021 Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced Sean P.
April 6th, 2021 Olema Oncology Appoints Oncology Biotech Executive Yi Larson, MBA, to Board of Directors Ms. Larson Brings Significant Biotech Operational Leadership and Global Healthcare Banking Expertise to Olema as the Company Continues to Advance Its Pipeline Longstanding Olema Director Dr. Frank McCormick to Transition from Board of Directors and Return to His Position as Chairman of Olema’s
March 17th, 2021 Olema Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates Advancing OP-1250 in metastatic, ER+ / HER2- breast cancer Phase 1/2 clinical trial Clinical trial agreements announced with Novartis and Pfizer to explore combination of OP-1250 with CDK4/6 inhibitors and PI3Kα inhibitor Approximately $382 million in gross proceeds raised across Series B, Series C
March 10th, 2021 Olema Oncology Announces Late-Breaking Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021 SAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation on

We are Olema Oncology.

Committed, tireless, and persistent.

We are Olema
Oncology.